Advertisement

Search Results

Advertisement



Your search for ,New matches 16916 pages

Showing 15401 - 15450


integrative oncology
palliative care

Integrating Spirituality Into Palliative Care Services

Over the past couple of decades, the oncology community has made great strides in mediating the psychosocial needs of our patients. However, a patient’s spirituality is a subjective and uncomfortable issue for many oncologists, which leaves a gap in the continuum of care. To reach a better...

You’ve Lived A Good Life

The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology (JCO). These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...

Yet Another Reason Why Dogs Are Our Best Friends

BookmarkTitle: Heal: The Vital Role of Dogs in the Search for Cancer CuresAuthor: Arlene WeintraubPublisher: ECW PressPublication date: October 13, 2015Price:  $16.95; paperback, 240 pages Comparative oncology, a fairly recent addition to the ever-evolving world of cancer research, studies the...

Racial Issues on the Road to Medicine

BookmarkTitle: Black Man in a White Coat: A Doctor’s Reflections on Race and MedicineAuthor: Damon Tweedy, MDPublisher: Picador, Macmillan PublishingPublication date: September 8, 2015Price: $26.00; hardcover, 304 pages Strained race relations over issues whose foundation is based on inequality...

The Highs and Lows of a Transplant Surgeon

Bookmark Title: Last Night in the OR: A Transplant Surgeon’s OdysseyAuthor: Bud Shaw, MDPublisher: Plume, division of Penguin GroupPublication date: September 15, 2015Price: $16.00; paperback, 304 pages Surgery has a distinct place in medicine. Surgeons cut deep into our bodies amid clusters of...

2015-2016 Oncology Meetings

DECEMBER American Society for Cell Biology Annual MeetingDecember 12-16 • San Diego, California For more information: http://ascb.org/2015meeting/ ESMO Asia 2015 CongressDecember 18-21 • Singapore For more information: www.esmo.org/Conferences/ESMO-Asia-2015-Congress JANUARY 2016 4th AACR-IASLC...

multiple myeloma

Ixazomib in Previously Treated Multiple Myeloma

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On November 20, 2015, ixazomib (Ninlaro) was approved by the U.S....

Lung Cancer: Hope From Science

The following essay by Paul A. Bunn, Jr, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org. I grew up...

palliative care

A Swiss Psychotherapist Gives Her Perspective on Optimal Palliative Care

Over the past few decades, the oncology community has incorporated new evidence-based therapies to address the psychosocial needs of patients with cancer, especially those with advanced disease. To bring a global perspective to this evolving discipline, The ASCO Post recently spoke with Monika...

issues in oncology

A Blueprint for Drug/Diagnostic Development: Expansion and Use of Curated Genetic Databases

In a continuation of a 2014 conference that explored regulatory considerations and strategies for next-generation sequencing, the Friends of Cancer Research, with support from Alexandria Real Estate Equities, Inc, Pasadena, California, met to discuss the issues and problems of coordinating drug and ...

integrative oncology

Foot Care in Oncology: The Cancer Patient From Ankle to Toe

There is as yet no clinical or research focus on foot complications that result from cancer therapies. Foot conditions, however, are common and have a considerable negative impact on patients’ ambulation, quality of life, and consistent dosing of antineoplastic agents.1-4 There are currently no...

Philip W. Kantoff, MD, Named Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center

Philip W. Kantoff, MD, has been named the new Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). An accomplished leader, physician, researcher, and mentor, Dr. Kantoff served the Dana-Farber Cancer Institute and Harvard Medical School (HMS) since 1987 in a...

Dario Marchetti, PhD, Named Director of the Center for Biomarkers

Dario Marchetti, PhD, recently joined Houston Methodist Hospital as the new Director of the Center for Biomarkers. Over the past 7 years, Dr. Marchetti’s laboratory at Baylor College of Medicine has made key discoveries in the biology and clinical use of circulating tumor cells. Dr. Marchetti’s...

cost of care

The Complex Interactions of Treatment Costs, Clinical Outcomes, and Patient Expectations

A clinical dilemma that is receiving a great deal of attention in the oncology community is the undue financial burden some patients face during their treatment and into survivorship. While much emphasis is put on methods to reduce and help patients navigate the complex payment system, little is...

issues in oncology
health-care policy

Cancer Care in Low-Resource Areas: Some Improvements Over the Years, but Serious Problems Remain

Low- and middle-income countries bear a larger share of the global cancer burden than does the developed world,” said Greta ­Massetti, PhD, Associate Director for Science, Centers for Disease Control and Prevention (CDC) Division of Cancer Prevention and Control and Co-Chair of the National Cancer...

global cancer care

Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Argentina

The ASCO Post is pleased to continue this special feature on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Argentina. The aim of this special feature is to highlight the global cancer burden for various countries of the world. For ...

MD Anderson Receives $22.2 Million in CPRIT Research Funding

The University of Texas MD Anderson Cancer Center was awarded more than $22 million in research grants from the Cancer Prevention and Research Institute of Texas (CPRIT). Thirty-six percent of funds awarded for Individual Investigator Awards went to MD Anderson faculty, as well as nearly 40% of...

Earn MOC Points With ASCO

The American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program promotes lifelong learning and the enhancement of the clinical judgment and skills essential for high-quality patient care. ASCO supports these principles by providing a variety of opportunities for oncology...

Barriers to Oncology Careers Focused on Cancer Prevention Could Be Addressed Through Education, Research Opportunities, Advocacy

A new study in the Journal of Clinical Oncology (JCO) on the barriers facing oncology professionals to a career focus in cancer prevention found that a lack of mentors and exposure during training, unclear career path, and uncertainty regarding reimbursement caused reluctance to incorporate...

Making a Difference for Patients: An Interview With Dr. Daniel F. Hayes, 2015–2016 President-Elect

Daniel F. Hayes, MD, FASCO, began his term as ASCO President-Elect this past June, and will serve as President in 2016–2017. A breast cancer specialist, he is Professor of Internal Medicine, the Stuart B. Padnos Professor in Breast Cancer, and the Clinical Director of the Breast Oncology Program at ...

Cancer Researchers and Clinicians Elected as 2015 AAAS Fellows

The American Association for the Advancement of Science (AAAS) Council elected 347 fellows for 2015, in recognition of their contributions to innovation, education, and scientific leadership. The tradition of electing AAAS fellows began in 1874 to recognize members for their scientifically or...

NCCN Foundation Appoints Three New Representatives to Board of Directors

The National Comprehensive Cancer Network (NCCN) Foundation has appointed three new representatives to its Board of Directors: Heather Kopecky, PhD, MBA; Marc Samuels, JD, MPH; and Susan Stein, MPH. There are currently 15 members of the Board of Directors, responsible for the strategic direction...

breast cancer

Regional Nodal Irradiation in Early Breast Cancer Yields Significant Disease-Free Survival Benefit in Two Trials

Two phase III trials recently reported in The New England Journal of Medicine indicated that the addition of regional nodal irradiation was associated with no or marginal overall survival benefit but significantly improved disease-free survival in patients with early-stage breast cancer.1,2 NCIC...

breast cancer

ASCO Clinical Practice Guideline: Use of Biomarkers to Guide Systemic Therapy for Women With Metastatic Breast Cancer

As reported in the Journal of Clinical Oncology by Catherine Van Poznak, MD, and colleagues, ASCO has issued a clinical practice guideline on the use of biomarkers to guide decisions on systemic therapy in women with metastatic breast cancer.1 The statement is based on an ASCO expert panel review...

lung cancer

Nivolumab Improves Overall Survival vs Docetaxel in Advanced Previously Treated Squamous Cell NSCLC

In a phase III trial reported in The New England Journal of Medicine, ­Julie Brahmer, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, and colleagues found that treatment with the programmed cell death protein 1 (PD-1) immune checkpoint inhibitor antibody nivolumab...

issues in oncology

Understanding Health-Care Disparities Among Lesbian, Gay, Bisexual, and Transgender Patients to Ensure More Effective Cancer Care

A new study examining the health-care needs of lesbian, gay, bisexual, and transgender/transsexual patients has found myriad disparities in access to cancer care.1 The researchers reviewed nearly 170 papers published over the past 15 years on the health-care needs among this population. Although...

NIH Awards City of Hope $2.2 Million Grant for Investigation of Chronic Graft-vs-Host Disease

The National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) has awarded a $2.2 million grant to help City of Hope researchers explore the underlying mechanisms of graft-vs-host disease, the leading cause of long-term sickness and death following...

breast cancer
issues in oncology

Closing the Racial Survival Disparity Gap in Breast Cancer: Models for Change From Chicago, New York, and Beyond

It has long been said that white women of European ancestry are more likely to be diagnosed with breast cancer, but African American women are more likely to die of it. This statement has introduced multiple articles on the topic of the racial survival disparity in breast cancer, including our own...

breast cancer

Convergence of Breast Cancer Incidence but Continued Divergence of Mortality in Black Women and White Women

In an article published in CA: A Cancer Journal for Clinicians, Carol E. ­DeSantis, MPH, and colleagues from the American Cancer Society reported that the incidence of breast cancer in black women has caught up to that in white women, whereas the risk of mortality continues to be higher in black...

NCCN Names Robert C. Young, MD, Interim Vice President of Oncology Research Program

The National Comprehensive Cancer Network (NCCN) has appointed Robert C. Young, MD, as Interim Vice President of the NCCN Oncology Research Program. Dr. Young brings to NCCN more than 45 years of oncology experience. He is President of RCY Medicine, a consulting service focused on cancer center...

skin cancer

Cobimetinib in BRAF-Mutant Unresectable or Metastatic Melanoma in Combination With Vemurafenib

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs On November 10, 2015, the U.S. Food and Drug Administration...

sarcoma

Trabectedin in Liposarcoma/Leiomyosarcoma: The Drug Is Approved, Now the Real Drug Development Begins!

Led by George Demetri, MD, of Dana-Farber Cancer Institute, Boston, expert medical oncology investigators from leading academic sarcoma centers and Janssen Pharmaceuticals employees performed a phase III trial in order to provide evidence for the U.S. Food and Drug Administration (FDA) approval of...

hematologic malignancies

Molecularly Targeted Therapy Brings New Hope to Patients With Relapsed/Refractory Hairy Cell Leukemia

The treatment of hairy cell leukemia is one of the great success stories in hematologic malignancies, with patients now having a survival that is only slightly inferior to an age-matched normal population. Purine analogs, such as cladribine, are the mainstay of first-line therapy, with...

hematologic malignancies
leukemia

BRAF Inhibition Successful in Relapsed/Refractory Hairy Cell Leukemia

In two phase II studies reported in The New England Journal of Medicine, ­Enrico Tiacci, MD, of the University of Perugia, Italy, and colleagues found that the BRAF inhibitor vemurafenib (Zelboraf) produced responses in nearly all patients with BRAF V600E–positive hairy cell leukemia that relapsed...

issues in oncology
geriatric oncology

Clinical Trial Design in Older Patients

Geriatrics for the Oncologist is guest edited by Stuart Lichtman, MD, FACP, FASCO, and developed in collaboration with the International Society of Geriatric Oncology (SIOG). Visit SIOG.org for more on geriatric oncology.   Increasing age is directly associated with an increasing risk of cancer,...

Mind-Body Therapies Were the Focus at the 12th International Conference of the Society for Integrative Oncology

Among the highlights at the 12th International Conference of the Society for Integrative Oncology (SIO) was a 1-day joint meeting on acupuncture, oncology, and fascia cosponsored by SIO, the Society for Acupuncture Research, the Fascia Research Society, and the Osher Center for Integrative...

2015 Review of Newly Approved Oncologic Therapies

Over the past year or so, a host of new agents were approved for the treatment of patients with various types of cancer (see related article on page 1). Patrick Medina, PharmD, of the University of Oklahoma College of Pharmacy, Oklahoma City, and Monique Giordana, PharmD, BCOP, of Regions...

U-M Cancer Center Names Bhramar Mukherjee, PhD, Associate Director for Population Science Research

The University of Michigan (U-M) Comprehensive Cancer Center has appointed Bhramar Mukherjee, PhD, as Associate Director for Population Science Research. Dr. Mukherjee is John D. Kalbfleisch Collegiate Professor of Biostatistics and Professor of Epidemiology at the U-M School of Public Health. She...

supportive care

Cancer Care Through Nonpharmacologic Symptom Management

Nonpharmacologic approaches to managing pain have a fairly robust base of science and research supporting their use but are not as widely accepted and understood as drug therapy in the realm of cancer care. In a breakout session at the 2015 Palliative Care in Oncology Symposium in Boston, experts...

breast cancer

Combining Molecular-Driven Approach and Immunotherapy to Improve Treatment for Patients With Inflammatory Breast Cancer

We have a responsibility to develop better treatment for inflammatory breast cancer,” Massimo Cristofanilli, MD, FACP, told participants at the 17th Annual Lynn Sage Breast Cancer Symposium in Chicago. As recently appointed Associate Director of Translational Research and Precision Medicine at the ...

solid tumors
hematologic malignancies

November Yields Record Number of FDA Approvals for New Oncology Drugs and Drug Indications

In 2014, the U.S. Food and Drug Administration (FDA) approved 9 new drugs and biologics in the treatment of cancer and added 10 notable new indications or formulations to existing drug labels, marking a year of significant progress in improving the quality of cancer care in the United States. So...

solid tumors
hematologic malignancies

FDA Oncology New Drug/New Indication Approvals for 2015

The following new hematology/oncology agents and expanded indications were approved by the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research in 2015: Alectinib (Alecensa), an ALK inhibitor, for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive...

Mixing Metaphors to Change the Language of Cancer

BookmarkTitle: Malignant Metaphor: Confronting Cancer MythsAuthor:  Alanna MitchellPublisher: ECW PressPublication date: September 15, 2015Price: $24.95; hardcover, 184 pages Illness is the night-side of life, a more onerous citizenship. Everyone who is born holds dual citizenship, in the kingdom...

breast cancer

Mohamed Bentires-Alj, PharmD, PhD, Honored With 2015 AACR Outstanding Investigator Award for Breast Cancer Research

Mohamed Bentires-Alj, PharmD, PhD, was recognized with the 8th Annual American Association for Cancer Research (AACR) Outstanding Investigator Award for Breast Cancer Research, funded by Susan G. Komen. He received the award at the 2015 San Antonio Breast Cancer Symposium. The AACR Outstanding...

breast cancer

AACR Recognizes Anne-Lise Børresen-Dale, DSc, With 2015 Distinguished Lectureship in Breast Cancer Research

Anne-Lise Børresen-Dale, DSc, Professor at the University of Oslo and Head of the Department of Genetics at the University Hospital Radiumhospitalet in Oslo, Norway, was honored with the 8th Annual American Association for Cancer Research (AACR) Distinguished Lectureship in Breast Cancer Research...

breast cancer

Breast Care Services at Henry Ford Health System Gains New Director, Three New Surgeons

Internationally renowned breast cancer surgeon Lisa A. Newman, MD, MPH, has joined Henry Ford Health System to lead its metro Detroit breast cancer program and new international breast cancer research center. She begins work in December as the Director of the Breast Cancer Program at Henry Ford....

solid tumors
prostate cancer

Decline in PSA Testing and Incidence of Early Prostate Cancer Coincide With 2012 Recommendation Against PSA Screening

Two recent studies1,2 found that the rates of prostate-specific antigen (PSA) screening have declined since the U.S. Preventive Services Task Force (USPSTF) recommended against PSA screening in 2012. One of those studies additionally found that the incidence of early-stage prostate cancer also...

Closure

The following essay by ­Kenneth R. Adler, MD, FACP, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org....

multiple myeloma

Hoping for a Cure

Unless you have a type of cancer that can be surgically removed or blasted into oblivion with chemotherapy or radiation therapy rendering a cure, having a chronic cancer like multiple myeloma robs you of a normal life. Learning to accept that fact is an adjustment. I was diagnosed with multiple...

New Medical Director of Supportive Care Services at Cedars-Sinai

Scott Irwin, MD, PhD, FAPM, FAPA, an expert in the fields of oncology supportive care, palliative care psychiatry, and psychosomatic medicine, has been named Medical Director of Supportive Care Services at Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute. Dr. Irwin will oversee oncology...

Advertisement

Advertisement




Advertisement